We were delighted to talk to Jean-Luc Van Laethem (Hôpital Universitaire Erasme, Université Libre de Bruxelles, Brussels, Belgium) about the efficacy and safety findings of the KEYNOTE-224 study (Clinical Trial Identifier: NCT02702414).
The abstract ‘Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase II KEYNOTE-224 study’ (ABSTRACT NUMBER: 297) was presented at the virtual ASCO Gastrointestinal Cancers Symposium 2021, 15-17 January, 2021.
Questions
- What was previously known about the use of pembrolizumab in the treatment of patients with advanced hepatocellular carcinoma (HCC)? (0:37)
- Could you tell us a little about the aims and design of KEYNOTE-224? (2:54)
- What were the efficacy and safety findings of the study? (4:50)
Disclosures: Jean-Luc Van Laethem has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of ASCO GI 2021 (Virtual).
